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A hydroxypyrone-basedmatrix metalloproteinase (MMP) inhibitor was synthesized and assayed for its inhibitory capacity towards
a panel of ten different MMPs.The compound exhibited selective inhibition towards MMP-12.The effects of inhibition of MMP-12
on endotoxemia and inflammation-induced blood-cerebrospinal fluid barrier (BCSFB) disruption were assessed both in vitro and
in vivo. Similar to MMP-12 deficient mice, inhibitor-treated mice displayed significantly lower lipopolysaccharide- (LPS-) induced
lethality compared to vehicle treated controls. Following LPS injection Mmp-12 mRNA expression was massively upregulated in
choroid plexus tissue and a concomitant increase in BCSFB permeability was observed, which was restricted in inhibitor-treated
mice. Moreover, an LPS-induced decrease in tight junction permeability of primary choroid plexus epithelial cells was attenuated
by inhibitor application in vitro. Taken together, this hydroxypyrone-based inhibitor is selective towards MMP-12 and displays
anti-inflammatory activity in vitro and in vivo.
1. Introduction
Matrix metalloproteinases (MMPs) are Zn2+-dependent
endopeptidases that are implicated in numerous physiolog-
ical processes such as reproduction, wound repair, devel-
opment, and immune function as well as pathological con-
ditions such as cancer, inflammation, neurodegenerative
disorders, and autoimmune diseases [1–4].The expression of
manyMMP familymembers is enhanced in endotoxemia [5–
7] and cecal ligation and puncture (CLP) [8–10], two mouse
models of sepsis, a highly mortal infectious disease, which
still lacks an efficient therapeutic treatment. Additionally,
studies using MMP inhibitors and MMP knockout mice
indicate that MMPs play a detrimental role in sepsis [9, 11–
13]. Moreover, several human data have directly correlated
higher levels of active MMP with lower rates of survival in
sepsis patients and some MMPs are considered as valuable
biomarkers in sepsis [8, 9, 14, 15].
Their detrimental role in several inflammatory diseases
justifies the development of specific MMP inhibitors, which
have been intensely sought after for over two decades but
with poor success [4, 16]. Most MMP inhibitors (MMPi)
consist of two distinct features: a peptidomimetic backbone
that interacts noncovalently with specific subsites of the
catalytic domain that govern substrate interaction and a
Zn2+-chelating moiety or zinc-binding group (ZBG) that
binds to the hydrolytic Zn2+-ion via coordinate-covalent
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bonds, rendering the enzyme inactive [16, 17].Themajority of
MMPi were initially synthesized containing hydroxamic acid
as ZBG which, although very potent, resulted in poor speci-
ficity, oral availability, or biocompatibility [18]. To circumvent
these problems, pyrone-based inhibitors emerged as superior
MMPi with known biocompatibility, good aqueous solubility,
and synthetic versatility [19, 20]. Based on this strategy, a spe-
cific MMP-3 pyrone-based inhibitor (AM-6) was developed
[21]. However, the specificity of AM-6was only characterized
for MMP-1, MMP-2, andMMP-3 and therefore, in this study,
we synthesized the same compound and screened it against a
broader range of MMPs to firmly ascertain MMP selectivity.
Surprisingly, the compound displayed specificity and potency
towards MMP-12. To accommodate these findings, we show
that the inhibitor protects against inflammation-induced
disruption of the blood-cerebrospinal fluid barrier both in
vitro and in vivo.
2. Materials and Methods
2.1. Chemistry. The target compound was synthesized
according to the literature with some modifications
(Scheme 1). The omission of an aqueous recrystallization
step leads to near-quantitative yields of the hydrolytically
unstable chlorokojic acid (1) without sacrificing purity.
Furthermore, 4-iodobenzylamine could be replaced with
4-bromobenzylamine (g), which is less costly and not
sensitive towards light and air [22]. The HCl/acetic acid
protocol as written in the original publication [21] did not
provide us with the final inhibitor in good yield (some 39%
crude yield). Reductive debenzylation (step i) did prove to be
a very reliable method to obtain the deprotected molecule.
The complete synthetic protocol is included below for the
convenience of the reader.
2.1.1. Chemistry: General Procedures. Proton NMR spectra
were recorded using a Bruker Avance 300 (300MHz) device
using tetramethylsilane as internal standard for CDCl3 and
DMSO-d6. 13C-NMR spectra were recorded using a Bruker
Avance 300 (75MHz) device, using the deuterated solvent
as an internal standard. FT-IR spectra were recorded on
a Bruker alpha-P. Reagents were purchased from various
companies, most notably TCI, Sigma-Aldrich, and Acros.
Reagents were not purified prior to use unless specifically
noted otherwise.
(1) Preparation of Compound 1 (Chlorokojic Acid). Kojic acid
(TCI, 15 g, 0.105mol) is placed in a round bottom flask
equipped with a magnetic stirring bar.The flask is cooled in
an ice bath and thionyl chloride (60mL) is slowly added after
which the ice bath is removed and themixture is placed under
an argon atmosphere. After stirring for 1.5 h a yellow mass
is filtered off and washed extensively with petroleum ether.
The product was an off-white solid (16.6 g, 98%): 1H-NMR
(DMSO-d6) 훿 4.6 (s, 2H, Cl-CH2-6), 6.6 (s, 1H, 5-H), and 8.1
(s, 1H, 2-H-) in agreement with the literature [19].
Table 1: Primer sequences used for gene expression analysis.
Primer Sequence
Ubc forward AGGTCAAACAGGAAGACAGACGTA
Ubc reverse TCACACCCAAGAACAAGCACA
Gapdh forward TGAAGCAGGCATCTGAGGG
Gapdh reverse CGAAGGTGGAAGAGTGGGAG
Mmp-12 forward CTGCTCCCATGAATGACAGTG
Mmp-12 reverse AGTTGCTTCTAGCCCAAAGAAC
Ubc, ubiquitin C; Gapdh, glyceraldehyde 3-phosphate dehydrogenase.
(2) Preparation of Compound 2 (Allomaltol). Chlorokojic acid
1 (2.5 g, 0.0156mol, 1 eq) is dissolved in water (8mL) and
heated to 50∘Cunder an argon atmosphere in aflask equipped
with a magnetic stirring bar. Zinc dust (2.1 g, 0.031mol, 2 eq)
is added. An aqueous solution of HCl (4.7mL, 0.055mol,
3.5 eq) is slowly added to the reactionmixture under vigorous
stirring, during which the temperature is increased to 70∘C.
After 4 h the excess zinc dust is filtered off while being hot,
and the resultant liquid is extracted with dichloromethane
(3 ∗ 20mL). The combined organic phase is dried over
magnesium sulfate and the solvent is removed by evaporation
under reduced pressure. The crude material is purified via
recrystallization from isopropanol to obtain an off-white
solid (1.2 g; 52%): 1H-NMR (CDCl3) 훿 2.3 (s, 3H), 6.2 (s, 1H),
and 7.8 (s, 1H) in agreement with the literature [19].
(3) Preparation of Compound 3 (3-Hydroxy-2-
(hydroxymethyl)-6-methyl-4H-pyran-4-one). Sodium
hydroxide (0.696 g, 0.017mol, 1.1 eq) is dissolved in water
(16mL). To this solution 2 (2 g, 0.016mol, 1 eq) a magnetic
stirring bar is added. The solution is stirred for 10 minutes
under an argon atmosphere. A 35% aqueous formaldehyde
solution (0.36mL, 0.017mol, 1.1 eq) is added and the mixture
is allowed to stir overnight. After acidification to pH 1 with
35% aqueous hydrochloric acid the mixture is cooled to
2∘C and allowed to stand overnight. The crystalline mass
is filtered off, washed with 5mL of water, and dried via
lyophilisation. An off-white solid is obtained (1.71 g, 71%):1H-NMR (DMSO-d6) 훿 2.26 (s, 3H), 4.38 (s, 2H), 5.36 (b, s,
1H), 6.21 (s, 1H), and 8.86 (b, s, 1H) in agreement with the
literature [19].
(4) Preparation of Compound 4 (3-(Benzyloxy)-2-
(hydroxymethyl)-6-methyl-4H-pyran-4-one). Sodium
hydroxide (0.56 g, 8.93mmol, 1.1 eq) is dissolved in water
(2.4mL) and added to a solution of 3 (2 g, 8.12mmol,
1 eq) in methanol (1.2mL) in a two-necked flask under
argon equipped with a reflux condenser, a septum, and
a magnetic stirring bar. The mixture is heated to reflux.
Benzyl bromide (1.7mL, 8.93mmol, 1.1 eq) is slowly added
and the mixture is allowed to stir overnight. The mixture
is concentrated in vacuo and taken up in dichloromethane
(approximately 20mL). Inorganic salts are filtered off. The
mixture is then extracted with 5%aqueous sodium hydroxide
(2 ∗ 20mL) and brine (1 ∗ 20mL). The organic phase is
dried with anhydrous sodium sulfate after which the solvent
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Scheme 1: Reagents and conditions: (a) SOCl2; (b) H2O, Zn, and HCl (aq); (c) NaOH (aq), CH2O; (d) NaOH (aq), MeOH, and BnBr; (e)
CHCl3, Et3N, DMSO, and SO3-pyridine; (f) acetone/water, sulfamic acid, and NaClO2; (g) THF, DCC, NHS, and 4-bromobenzylamine; (h)
toluene, K2CO3 (aq), PPh3, Pd(OAc)2, and 1,1耠-biphenyl-4-boronic acid; (i) MeOH/DCM, Pd/C, and H2.
is removed under reduced pressure. The solid is dissolved
in as little dichloromethane as possible after which heptane
(or petroleum ether) is added until no more precipitation
occurs.The precipitate is filtered off and dried to yield a white
to off-white powdery solid (2.3 g, 73%): 1H-NMR (CDCl3) 훿
2.25 (s, 3), 2.28–4.30 (d, 2H, 6.8Hz), 5.18 (s, 2H), 6.19 (s, 1H),
and 7.37 (s, 5H) in agreement with the literature [19].
(5) Preparation of Compound 5 (3-(Benzyloxy)-6-methyl-
4-oxo-4H-pyran-2-carbaldehyde). Compound 4 (2 g, 1 eq,
8.18mmol) is dissolved in 37.8mL chloroform and 10.2mL
DMSO. To this mixture triethylamine (7mL, 0.050mol, 6 eq)
and pyridine (0.1mL) are added. The mixture is stirred
in an ice bath under argon using a magnetic stirring bar
until a temperature of 3–5∘C is reached. Sulfur trioxide-
pyridine complex (6.48 g, 0.040mol, 5 eq) is subsequently
added and the mixture is allowed to stir overnight. It is then
extracted (2 ∗ 20mL water, 1 ∗ 20mL brine) and dried over
anhydrous sodium sulfate. The solvent is removed under
reduced pressure using a rotavapor equipped with a cold trap
(dry ice/isopropanol) to obtain the crude product as orange
oil. This is diluted with 10mL diethyl ether and transferred
onto a flash column packed with silica/diethyl ether. After
eluting with diethyl ether the solvent is removed under
reduced pressure using a rotavapor equippedwith a cold trap.
Remaining volatiles are removed by a stream of nitrogen.
A white to yellow crystalline solid is obtained (1.38 g, 69%):1H-NMR (CDCl3) 훿 2.32 (s, 3H), 5.49 (s, 2H), 6.31 (s, 1H),
7.35 (s, 5H), and 9.85 (s, 1H) in agreement with the literature
[19]; FT-IR 1690.33 cm−1 (C=Oaldehyde), 1641.24 cm−1 (C=O
pyrone), 1613.12 cm−1, and 1583.88 cm−1 (C=C pyrone).
(6) Preparation of Compound 6 (3-(Benzyloxy)-6-methyl-
4-oxo-4H-pyran-2-carboxylic acid). Compound 5 (1.57 g,
6.4mmol, 1 eq) is dissolved in acetone/water (20mL/20mL)
with a magnetic stirring bar. Sulfamic acid (0.86 g, 8.9mmol,
1.4 eq) and sodium chlorite (80%, 0.76 g, 6.7mmol, 1.05 eq)
are added and the mixture is allowed to stir for 1 h in an
open vessel. Some precipitation may occur. The mixture is
subsequently evaporated under reduced pressure to remove
the acetone after which the crude product is filtered off and
washed with a small amount of ethanol.The product is then
dried in vacuo to obtain a stark white powder (1.3 g, 78%):1H-NMR (DMSO-d6) 훿 2.29 (s, 3H), 5.10 (s, 2H), 6.40 (s,
1H), and 7.32–7.45 (m, 5H) in agreement with the literature
[19]; FT-IR 1720.37 cm−1 (C=O acid), 1625.50 cm−1 (C=O
pyrone), 1554.48 cm−1 and 1496.36 cm−1 (C=C pyrone), and
MP (precipitated from water/acetone) 180∘C.
(7) Preparation of Compound 7 (3-(Benzyloxy)-N-(4-
bromobenzyl)-6-methyl-4-oxo-4H-pyran-2-carboxamide).
Compound 6 (0.1 g, 0.38mmol, 1 eq) is dissolved in dry
tetrahydrofuran (4.16mL) in a flame-dried round bottom
flask equipped with a magnetic stirring bar under an argon
atmosphere. N-Hydroxysuccinimide (0.045 g, 0.39mmol,
1.02 eq) is added and the mixture stirred for 30min.
Dicyclohexylcarbodiimide (0.079 g, 0.38mmol, 1 eq) is
added as a solid and the mixture is stirred for an additional
3 h at RT under an argon atmosphere. Dicyclohexylurea is
filtered off and the precipitate is washed with tetrahydrofuran
(2mL). 4-Bromobenzylamine (0.05mL, 0.385mmol, 1.01 eq)
is added to the filtrate in a dried round bottom flask equipped
with a magnetic stirring bar and a reflux condenser under an
argon atmosphere.Themixture is heated to 60∘C and allowed
to stir overnight. The solvent is removed under reduced
pressure and the residue taken up in chloroform. This
solution is transferred to a chromatography column (silica,
eluent chloroform/methanol 1%). After chromatography,
the product is obtained as an off-white solid (0.15 g, 91%):1H-NMR (CDCl3) 훿 2.37 (s, 3H), 4.3–4.38 (d, 2H, 퐽 = 5.6),
5.33 (s, 2H), 6.28 (s, 1H), 6.9–7.5 (m, 9H), and 8.06 (b, s,
1H); FT-IR 3363.82 cm−1 (](NH)), 1677.31 cm−1 (](C=O)
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Figure 1: Chemical structure and specificity of the synthesized MMP inhibitor. (a)The target compound consists of a Zn2+-binding group
(ZBG) and a terphenyl which resides in the deep S1耠 pocket of the MMP catalytic domain [21]. (b) List of in vitro determined IC50 values
(휇M) which indicates that the inhibitor is very specific towards MMP-12with an IC50 in the nanomolar range. (c) Fitted dose-response curve
relation to MMP-12 used to calculate the IC50.
pyrone), 1643.58 cm−1 (amide I band), 1621.41 cm−1 (](C=C)
pyrone), 1584.93 cm−1 (](C=C) pyrone), 1536.21 cm−1 (amide
II band), and MP (recrystallized from methanol) 118∘C.
(8) Preparation of Compound 8 (N-([1,1耠:4耠,1耠耠-Terphenyl]-
4-ylmethyl)-3-(benzyloxy)-6-methyl-4-oxo-4H-pyran-2-
carboxamide). Compound 7 (90mg, 0.21mmol, 1 eq) is
dissolved in toluene in a round bottom flask equipped with
a reflux condenser, magnetic stirring bar, and an argon
atmosphere. To this mixture are added aqueous potassium
carbonate (2M solution, 10mL), triphenylphosphine
(5.5mg, 0.021mmol, 0.1 eq), [1,1耠-biphenyl]-4-ylboronic acid
(41.5mg, 0.21mmol, 1 eq), and palladium acetate (4.6mg,
0.02mmol, 0.1 eq) after which the mixture is heated to 135∘C
with vigorous stirring. The mixture is allowed to stir for
24 h before being extracted with toluene (3 ∗ 20mL) and
dried over sodium sulfate and the solvent is removed under
reduced pressure. The crude product is purified via column
chromatography (silica, chloroform/1-2% methanol): 1H-
NMR (CDCl3) 훿 2.37 (s, 3H), 4.44–4.5 (d, 2H, 퐽 = 5.7Hz),
5.34 (s, 2H), 6.29 (s, 1H), 7.10–7.75 (m, 18H), and 8.12 (b, 1H).
(9) Preparation of Compound 9 (N-([1,1耠:4耠,1耠耠-Terphenyl]-
4-ylmethyl)-3-hydroxy-6-methyl-4-oxo-4H-pyran-2-
carboxamide). Compound 8 (186.5mg) is dissolved in
dichloromethane/methanol (70/30, 35mL) in a thick-walled
glass vessel. After flushing with argon, the hydrogenation
catalyst is added (10% palladium on carbon). The vessel
is placed in a shaker-type hydrogenation apparatus and
placed under 40 psi hydrogen gas for 20 h after flushing
with hydrogen gas to remove traces of oxygen. The
catalyst is filtered off and the filtrate washed with 10mL
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Figure 2: In vivo and in vitro effect of MMP-12 inhibition in endotoxemia. (a) Survival in function of time of MMP-12+/+ (black) and MMP-
12−/− (grey) mice following i.p. challenge with a lethal dose of LPS. (b) Survival in function of time of C57BL/6 mice injected with vehicle
(black) or MMP-12i (grey) following i.p. challenge with a lethal dose of LPS. (c) RelativeMmp-12 expression in choroid plexus tissue isolated
before and 1, 4, and 8 hours after LPS challenge (푛 = 3-4). (d) Relative permeability of the blood-CSF barrier determined by measuring
leakage of fluorescently labeled dextran (4 kDa) from the blood into the CSF 8 hours after LPS challenge in vehicle (black) and MMP-12i
(grey) treated wild type mice, compared to PBS injected wild type mice. (e) Normalized resistance measured at low frequency using the ECIS
instrument of primary choroid plexus epithelial cells incubated with vehicle (black), 1000 ng/mL LPS (black dotted line), and 1000 ng/mL
LPS pretreated with 1 휇M MMP-12 inhibitor (grey) (푛 = 3). Data are presented as means ± standard error of mean (sem). Survival curves
were compared using a log-rank test. Other data were analyzed by Student’s t-test. ∗ 0.01 ≤ 푃 < 0.05; ∗∗ 0.0001 ≤ 푃 < 0.001; ∗∗∗∗푃 < 0.0001.
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dichloromethane/methanol (50/50). The combined organic
phase is evaporated in vacuo to yield an orange solid
(138.5mg, 90%): 1H-NMR (CDCl3) 2.24 (s, 3H), 4.6 (s,
2H), 6.16 (s, 1H), and 7–7.8 (m, 13H); FT-IR 2339.5 cm−1
(OH), 1633.1 cm−1 (amide I), 1591.8 cm−1 (C=O pyrone),
1537.5 cm−1 (amide II), 1483.9 cm−1 (C=C pyrone), and MP
(recrystallized from toluene) 253–270∘C.
2.2. Recombinant MMP Assays. The specificity of the
synthesized inhibitor was determined in vitro against a
panel of ten human recombinant MMP catalytic domains
using a fluorescent assay kit (BML-AK016, Enzo Life
Sciences). Briefly, the compound was dissolved in dimethyl
sulfoxide (DMSO) and further diluted in assay buffer
(50mM HEPES, 10mM CaCl2, 0.05% Brij-35, and pH 7.5).
Ten MMPs (MMP-1, MMP-2, MMP-3, MMP-7, MMP-8,
MMP-9, MMP-10, MMP-12, MMP-13, and MMP-14) were
individually incubated with varying concentrations of
inhibitor for one hour at 37∘C, followed by addition of a
quenched fluorogenic substrate (OmniMMP fluorogenic
substrate Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 [Mca
is (7-methoxycoumarin-4-yl)-acetyl; Dpa is N-3-(2,4-
dinitrophenyl)-L-훼-훽-diaminopropionyl], 4 휇M in assay).
The assays were performed in black, clear bottom, NBS
Greiner 96-well plates (655906, Greiner Bio-One) and
fluorescence (휆ex = 325 nm, 휆em = 405 nm) was measured at
60 sec intervals for 30min with a FlexStation II microplate
reader running SoftMax Pro 5.3 (Molecular Devices). After
each fluorescentmeasurement the well plates were shaken for
2 sec to agitate the reagents. In each experiment we included
a blank, a substrate control (substrate only in assay buffer),
a positive control (NNGH, 1.3 휇M final concentration), and
negative control (only substrate and inhibitor in assay buffer).
The latter was implemented to exclude possible interference
of the inhibitor with the substrate. To confirm the potency
againstMMP-3 andMMP-12, separate assays were performed
using human recombinant MMP-3 (72006, AnaSpec) and
MMP-12 catalytic domains (55525-1, AnaSpec) and quenched
fluorescent substrate QXL 520-Pro-Leu-Ala-Tyr-Trp-Ala-
Arg-Lys(5- FAM)-NH2 (휆ex = 485 nm, 휆em = 538 nm,
60577-01, AnaSpec). The IC50 values were determined in a
single experimental run in duplicate. Data analysis and curve
fitting for determination of IC50 values were performed in
GraphPad Prism 6.
2.3. Animals. Female C57BL/6J (8–10 weeks old) mice were
purchased from Janvier Labs (France) andMMP-12 knockout
mice (MMP-12−/−) (in C57BL/6J background together with
littermate MMP-12+/+ controls) were obtained from Dr.
Steven Shapiro (University of Pittsburgh, USA). C57BL/6 and
MMP-12−/− mice were housed with 4–6 mice/cage with ad
libitum access to food and water and with a 14-hour light/10-
hour dark cycle in a specific pathogen-free animal facility
and conventional facility, respectively. All experiments were
approved by the Ethics Committee of the Faculty of Sciences
of Ghent University.
2.4. Endotoxemia Model and MMP-12i Treatment. Endo-
toxemia was induced by intraperitoneal (i.p.) injection of
lipopolysaccharide (LPS) from Salmonella enterica serotype
abortus equi (Sigma) dissolved in PBS. The dose was
200휇g/20 g body weight (the LD100 dose for C57BL/6mice).
Control animals received i.p. injections of PBS. Rectal tem-
perature was measured periodically after challenge. 100 휇g
MMP-12i (1 휇g/휇L) or vehicle control was administered
intraperitoneally at different time points: 15min before and
3 and 6 hours after LPS administration.
2.5. Gene Expression Analysis. For isolation of total RNA
from in vivo choroid plexus samples, mice were anesthetized
with ketamine/xylazine and perfusedwith PBS supplemented
with bromophenol blue. Brains were dissected from the skull
and choroid plexus from the third and fourth ventricles were
dissected under a dissection microscope. Total RNA was
isolated at different time points after LPS injection with the
RNeasy kit (Qiagen). RNA concentration and purity were
determined spectrophotometrically using the NanoDrop
ND-1000 (NanoDrop Technologies). cDNA was made by
using iScript cDNA Synthesis Kit (Bio-Rad) with 500 ng
starting material and QPCR was done using the SensiFAST
SYBR No-ROX Kit (Bioline) on the Light Cycler 480 system
(Roche). Expression levels of Mmp-12 were normalized to
the expression of the two most stable housekeeping genes,
Ubc and Gapdh, which were determined using the geNorm
Housekeeping Gene (HKG) Selection Software [23]. Primer
sequences can be found in Table 1.
2.6. Blood-CSF Barrier Permeability Leakage In Vivo. One
hour before CSF isolation, mice were injected i.v. with
75mg/kg body weight of FITC-labeled dextran (4 kDa,
Sigma). They were perfused with 0.9% saline to remove all
labeled dextran in the circulation. CSF was obtained using
the cisterna magna puncture method as described previously
[24]. In brief, borosilicate glass capillary tubes (B100-75-
15, Sutter Instruments) were used to pull needles on the
Sutter P-87 flamingmicropipette puller (pressure 330Pa, heat
index 300). Before sampling CSF, mice were sedated with
ketamine/xylazine. The incision site was sterilized with 70%
ethanol, and cisterna magna was exposed by cutting skin
and muscle tissue on the posterior side of the skull. The
head of the mouse was placed at an angle of 135 degrees and
CSF was collected by inserting the trimmed needle into the
fourth ventricle by piercing the cisternamagna.ACSF sample
of 2 휇L was diluted 25-fold in sterile PBS and leakage into
this brain compartment was determined by measurement of
fluorescence with 휆ex/휆em = 488/520 nm.
2.7. Blood-CSF Barrier Permeability In Vitro. Culturing pri-
mary mouse choroid plexus epithelial cells was done as
described [25]. In brief, 2–9-day-old pups were decapitated
and brains were isolated. Choroid plexuses from all four
ventricles were isolated under a dissection microscope. The
cells were dissociated enzymatically by incubating them for
5–7min with pronase (isolated from Streptomyces griseus,
Sigma). Digestion was stopped by adding an excess of
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HBSS buffer and the cells were washed twice with HBSS.
The cell pellet was resuspended in DMEM-F12 culture
medium and plated on laminin-coated plates. Two days
later, they were shifted to DMEM-F12 containing cytosine
arabinoside (Ara-C) to eliminate growth of fibroblasts. Cul-
tures were maintained at 37∘C in 5% CO2. Purity of the
cultures was confirmed by checking the levels of transthyretin
(TTR) both by qPCR and by immunostaining. Primary
CPE cells retained the epithelial and the barrier properties
which were confirmed by staining for E-cadherin, ZO-1,
and occludin. The electric cell-substrate impedance (ECIS)
technique (Applied Biophysics) was used to monitor bar-
rier properties as described before [26]. 250.000 cells per
well were seeded onto laminin-coated 8W10E array plates
(Applied Biophysics) and the array holder was placed in a
standard cell culture incubator (37∘C, 100% humidity, and
5% CO2). Array plates were connected to the instrument
and multifrequency measurements were started. After ∼16
hours, a stable impedance at low and high frequency was
obtained and cells were incubatedwith vehicle or 1휇MMMP-
12i, followed 1 hour later by vehicle or LPS (1000 ng/mL).
3. Results and Discussion
3.1. Inhibitor Specificity. Compound 9 (Figure 1(a)) was
assessed for its inhibitory properties towards an array of ten
different MMPs using a fluorescent in vitro assay. For all
testedMMPs, the compound is poorly potent againstMMP-1,
MMP-3, MMP-7, MMP-9, MMP-10, and MMP-13, reflecting
IC50 values higher than 50 휇M (Figure 1(b)).The compound
displays slightly better inhibitory activity towards MMP-2,
MMP-8, andMMP-14 as the apparent IC50 values are situated
between 2휇M and 50 휇M. But most importantly towards
MMP-12 the compound reveals very potent inhibitory activ-
ity. The initial screen revealed an apparent IC50 value for
MMP-12 below 2 휇M and when performing a detailed dose-
response experiment using a more specific substrate for
MMP-12 (Substrate XIII, AnaSpec) a nonlinear regression
analysis indicated that at higher inhibitor concentrations an
inhibitory plateau (72 ± 1.75%) is reached with a relative
IC50 of 177 nM (Figure 1(c)). Although the use of a different
substrate can potentially influence the kinetic readout, a
comparison between the fluorescent in vitro assay kit and the
use of Substrate XIII resulted in similar inhibitor potencies
(data not shown), which justifies the use of the more specific
substrate for MMP-12. Taken together, these data indicate
that the synthesized compound is a potent and fairly specific
inhibitor of MMP-12 and therefore from Section 3.2 onwards
it will be referred to as MMP-12i. The discrepancy between
Puerta et al. [21] and this study regarding the inhibitory
selectivity towards MMP-12 over MMP-3 could in part be
explained by the strong pH-dependence of inhibitor potency
for human MMP-3 [27]. Both MMP-3 and MMP-12 have a
deep pocket S1耠 subsite [28] in which the terphenyl can reside
[21]. However, MMP-3 is uniquely characterized by a sharp
optimum at pH 6 for efficient catalysis and inhibition and
this is drastically reduced at neutral pH by structural changes
in the S1耠 pocket and ionization of inhibitor residues [27]. In
contrast to the study of Puerta and colleagues, the compound
was tested in physiologically relevant pH 7.5 to accommodate
a large array of MMPs. Importantly, the pH-dependence of
inhibitor-MMP3 interactions typically gives rise to a change
in IC50 values not larger than one order of magnitude [27]
as opposed to the three orders of magnitude we established
here, so other factors might be at play. Because of this and the
observed potency towards MMP-12 we further validated the
biological relevance of the compound in the context ofMMP-
12.
3.2. In Vitro and In Vivo Effect of MMP-12 Inhibition. Endo-
toxemia, that is, systemic administration of lipopolysaccha-
ride (LPS), induces systemic inflammation and eventually
lethality in mice. We have previously shown that mice can
be protected from LPS-induced lethality by administration
of a broad spectrum MMP inhibitor BB-94 [9] and several
MMPs appeared to play a role in the LPS-induced lethality
[8, 11–13]. Here, we studied the effect of MMP-12 deficiency
on the LPS sensitivity by using MMP-12−/− mice. As shown
in Figure 2(a), MMP-12−/− mice display a partial protection
to an LD100 dose of LPS, indicating that MMP-12 plays a
detrimental role in the LPS-induced lethality. To verify this,
we treated wild type mice with the MMP-12i and challenged
them with LPS (Figure 2(b)). MMP-12i treatment resulted in
a significant reduction in LPS-induced lethality compared
with vehicle treated mice, which again demonstrates that the
compound most likely targets MMP-12. Systemic inflamma-
tion is known to be associatedwith loss of blood-brain barrier
integrity and this has been correlated with lethality [29]. Next
to the most studied endothelial blood-brain barrier (BBB),
we have previously shown that the blood-cerebrospinal fluid
barrier (BCSFB) which is formed by the choroid plexus
epithelium (CPE) is also affected in response to systemic
LPS administration [9].mRNAexpression analysis of choroid
plexus tissue revealed 500-fold upregulation of Mmp-12
upon systemic LPS administration (Figure 2(c)), associated
with an increase in BCSFB permeability (Figure 2(d)). Inter-
estingly, the loss of BCSFB permeability was significantly
reduced when endotoxic mice were treated with our MMP-
12i (Figure 2(d)). Finally, we analyzed the effect of the MMP-
12i on the BCSFB in vitro.Therefore, primary CPE cells were
isolated and plated onto electrical cell impedance sensing
(ECIS) arrays containing gold electrodes. ECIS is a real-time,
label-free, impedance-basedmethod used to study the barrier
properties of cells grown in culture. After reaching conflu-
ency, cells were incubated with LPS or LPS supplemented
with MMP-12i and compared to untreated cells. LPS resulted
in a drop in normalized resistance compared to control and
this was significantly reduced in the presence of MMP-12i
(Figure 2(e)). These data clearly show that MMP-12 plays a
role in the observed LPS-induced loss of BCSFB integrity.
4. Conclusion
In summary,we report the synthesis and biological evaluation
of a hydroxypyrone-based MMPi with excellent potency
and specificity towards MMP-12. Both in vivo and in vitro
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studies on the effects of the target compound on endotoxemia
and BCSFB integrity clearly indicate a role for MMP-12 in
these inflammatory processes and establish the use of this
compound in a biological context.
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